New commercial model in the works at GSK
Executive Summary
GlaxoSmithKline is jumping on the bandwagon to restructure as the sales environment shifts. CEO Andrew Witty says the company is remodeling its U.S. operations, but did not offer specifics during a third quarter earnings call Oct. 22. The firm continues to take a hit from generic competition in the U.S. and the Avandia (rosiglitazone) controversy (1"The Pink Sheet," June 16, 2008, p. 25)
You may also be interested in...
Hypertensives May Get Class Outcome Labels; Industry Wary Of Broad Efficacy
Two major drug companies with significant hypertension profiles are welcoming the proposed inclusion of class-wide cardiovascular outcomes data in antihypertensive drug labeling - in contrast to other firms that commented on the FDA draft guidance
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.